Ten patients with idiopathic hypertrophic subaortic stenosis were studied with right and transseptal left heart catheterization. All patients had the expected increases in subvalvular systolic gradients with isoprenaline infusion, amyl nitrite inhalation, exercise, and performance of the Valsalva manoeuvre. These stimulatory procedures were repeated after intravenous infusion of practolol (6oo or goo .ug/kg). This resulted in partial amelioration of exercise and isoprenaline-induced gradient augmentation, with no effect on resting gradients. 
Idiopathic hypertrophic subaortic stenosis is a wellrecognized syndrome in which functional subvalvular outflow tract obstruction may be variable and may be modified by various physiological and pharmacological manoeuvres (Wigle et Brockenbrough, Braunwald, and Morrow, I96I) . Outflow tract obstruction has been shown to increase with isoprenaline infusion (Wigle et al., I965; Braunwald and Ebert, i962) , amyl nitrite inhalation (Wigle et al., i965) , and performance of the Valsalva manoeuvre (Braunwald et al., I964) . Narrowing of aortic pulse pressure with increase in left ventricular-aortic (LV-Ao) gradients has been noted in post-extrasystolic cycles (Brockenbrough et al., I96I) . Since Harrison's studies with nethalide in I964 (Harrison et al., I964) , betaadrenergic blockade has been one of the preferred modes of medical treatment of patients with idiopathic hypertrophic subaortic stenosis. Several investigators have reported significant improvement in terms of effort tolerance and decrease in angina pectoris after the prolonged oral administration of propranolol (Cohen and Braunwald, I968; Adelman et al., 1970; Rosenblum et al., I967; Cherian et al., I966; Flamm, Harrison, and Hancock, I968) . Propranolol has also been shown to ameliorate the increases in subaortic obstruction caused by exercise or isoprenaline infusion (Cherian et al., I966; Flamm et al., I968) .
Practolol is a new cardioselective beta-adrenergic blocking agent which differs from propranolol in several respects. Unlike the latter, practolol is cardioselective with little or no effect on peripheral vasculature or bronchial smooth muscle (Dunlop and Shanks, I968) . Practolol lacks 'quinidine-like' or 'membrane-like' properties found in propranolol, and thus may exert less direct myocardial depression (Dunlop and Shanks, I968; Somani and Laddu, I969) . In addition, practolol possesses mild intrinsic sympathetic properties (Dunlop and Shanks, I968; Barrett and Carter, 1970; Wale, Pun, and Rand, I969) . These properties suggest that practolol may have fewer side effects than propranolol in causing airway obstruction and for producing congestive heart failure.
Although practolol has been employed widely for the treatment of arrhythmias and angina in patients with ischaemic heart disease (Jewitt, Mercer, and Shillingford, I969; Gent, Davis, and McDonald, 1970; Coltart, 1970; Wilson et al., I969; Atkins, Blomqvist, and Cohen, I970) After measurement of resting haemodynamic parameters, 9 patients performed the Valsalva manoeuvre, 9 inhaled amyl nitrite, and 9 received a bolus injection of isoprenaline (3 ,ug) . Before each such manoeuvre, control measurements of LV-Ao gradients were made and, after these, the gradients were measured at the point of peak effect. Cardiac outputs at rest and supine exercise using a bicycle ergometer were estimated by indocyanine green dye dilution techniques in 7 patients and by the Fick method in 2.
After these measurements, practolol was given intravenously over a io-minute period: seven patients received 6oo ,tg/kg and three goouLg/kg. After a 20-minute rest interval, the procedure described above was repeated. Exercise loads and drug challenges were the same for each patient before and after drug administration. All exercise determinations were made between the fifth and tenth minutes of sustained exercise. A t test for paired data was used to determine statistical significance in comparing pre-and post-practolol effects.
Results
The resting haemodynamic data before and after practolol administration are shown on Table i . Two of the patients had no LV-Ao gradient at rest, while the remaining 8 had resting gradients ranging from io to 88 mmHg. All patients displayed increases in gradients with the Valsalva manoeuvre, amyl nitrite inhalation, and isoprenaline injection (Table 2 ). In addition, increased gradients were uniformly noted in postextrasystolic contractions. Thus, all io patients fulfilled completely the diagnostic criteria for idiopathic hypertrophic subaortic stenosis. The mean resting cardiac output for the group was 5-2 1./min, which decreased slightly to 4.7 l./mi after the administration of practolol (P < o0o5).
Resting stroke volume decreased minimally from 73-4 to 71-1 ml, while heart rate went from 73-2 to 69 i beats a minute. The changes in stroke volume and rate were not statistically significant. The mean resting gradient was unaffected by practolol (30o8 mmHg before and 3I-4 after). The response to amyl nitrite inhalation was not altered after practolol (Fig. i) . Before practolol administration, the LV-Ao gradient after amyl nitrite rose from 33 tO 7I -6 mmHg. After practolol, the gradient rose from 32-3 to 66-4 mmHg. The pre-and postpractolol responses were similar and statistically undistinguishable (Fig. 2) .
Before practolol, isoprenaline injection produced an average gradient increase of 76-6 mmHg, from 38 I to II4-4mmHg ( Fig. 3 and 4) . The heart rate increased by 25 beats a minute from a rate of 716 to 96-9. After practolol, the average gradient rose only 44-6 mmHg, rising from 30-2 to 74-2 mmHg, and the heart rate increased from 67-2 to 8o-i. The blunting of both gradient and heart rate responses was significant (P < o-oi). There was, however, indiVidual variation among patients. Two patients (Cases 8 and 9) showed complete block of the isoprenaline stimulation. Five patients (Cases I, 3, 6, 7, and io) demonstrated partial amelioration, and 2 patients (Cases 4 and 5) had no alteration of the isoprenaline effect after practolol. One of these latter 2 patients (Case 5) received the larger dose of 900 ,ug/kg. His heart rate increased by 5 beats a minute with isoprenaline injection after practolol, whereas it had increased by i6 beats a minute before practolol. The other non-responder (Case 4) received 6oo ,ug/kg of practolol and had no block of heart rate response to isoprenaline after practolol.
The response of the systolic gradient to supine exercise is illustrated in Fig. 5 and 6 . Before practolol, exercise induced a mean rise of i6-6 mmHg in LV-Ao gradients, with an associated increase in heart rate of 22 beats a minute. After practolol there was a small increase in both gradient and heart rate (I5-6 beats/min). Both of these changes were significant (P < o0os). Again Practolol had no effect on resting gradients in the present study, whereas Flamm et al. (I968) showed that propranolol in doses of I50 ,ug/kg decreased resting LV-Ao gradients.
In a previous report from this laboratory (Flamm et al., I968) , ii patients with idiopathic hypertrophic subaortic stenosis were studied before and after the intravenous administration of propranolol (I50 ,ug/kg). The study design was identical to the present report and showed that propranolol, given acutely, produced blockade of the isoprenaline augmentation of LV-Ao gradients.
The results of the present study differ in that practolol seemed to produce only partial blockage of the isoprenaline effect on LV-Ao gradients. This was associated with only a partial block of isoprenaline's heart rate effect as well. In addition, the exercise-induced tachycardia and gradient were only partially ameliorated by practolol in the present study, with 3 patients showing no practolol effect. One can conclude, therefore, that acute intravenous doses of 6oo to goo Vg/kg of practolol provide less amelioration of subvalvular obstruction than 150 jig/kg of intravenous propranolol.
The dose of practolol chosen for this study was aimed at a level four to six times the amount of propranolol (I50 jig/kg) which was known to block the isoprenaline effect in patients with idiopathic hypertrophic subaortic stenosis. This ratio was based on several studies in animals and humans. Dunlop and Shanks (I968) reported that practolol's betablocking capability was one-third to one-fourth as potent as propranolol in a dog study. Barrett concluded that the practolol to propranolol ratio was I: 3 in a study performed on rats (Barrett and Carter, I970) . Wale showed that the dose of practolol required to produce a 50 per cent reduction of isoprenaline-induced tachycardia was seven times as great as propranolol (Wale et al., I969) . A similar ratio of I:7 was reported in a dog study by Hashimoto et al. (I969).
Fitzgerald and Scales (I968) felt that the practolol to propranolol dose ratio in humans was about 3 orthat the amount of practolol required to reduce angina and prolong treadmill exercise tolerance was about two to four times as great as propranolol (Coltart, I970; Wilson et (Flamm et al., I968) . The interruption of this vicious cycle is the rationale for treating the asymptomatic patient with idiopathic hypertrophic subaortic stenosis. Since propranolol appears to be more effective than practolol in this respect, it seems to be the preferred agent for treatment. 
